First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5043500_AE43500_0